{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T13:38:17Z","timestamp":1783517897669,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2014,8,12]],"date-time":"2014-08-12T00:00:00Z","timestamp":1407801600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1007\/s11033-014-3613-8","type":"journal-article","created":{"date-parts":[[2014,8,11]],"date-time":"2014-08-11T07:04:00Z","timestamp":1407740640000},"page":"7265-7271","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Single nucleotide polymorphism of CYP3A5*3 contributes to clopidogrel resistance in coronary artery disease patients among Tamilian population"],"prefix":"10.1007","volume":"41","author":[{"given":"Rajendran","family":"Priyadharsini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak Gopal","family":"Shewade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumaresan","family":"Subraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byrappa Kempalalakshmamma","family":"Ravindra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurusamy","family":"Umamaheswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Aibor","family":"Dkhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhosh","family":"Satheesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magadi Gopalakrishna","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil K.","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrasekaran","family":"Adithan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,12]]},"reference":[{"key":"3613_CR1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s11886-011-0194-1","volume":"13","author":"E Camilleri","year":"2011","unstructured":"Camilleri E, Jacquin L, Paganelli F, Bonello L (2011) Personalized antiplatelet therapy: review of the latest clinical evidence. Curr Cardiol Rep 13:296\u2013302","journal-title":"Curr Cardiol Rep"},{"key":"3613_CR2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/clpt.2010.316","volume":"89","author":"AL Beitelshees","year":"2011","unstructured":"Beitelshees AL, Horenstein RB, Vesely MR, Mehra MR, Shuldiner AR (2011) Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions. Clin Pharmacol Ther 89:455\u2013459","journal-title":"Clin Pharmacol Ther"},{"key":"3613_CR3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.thromres.2011.04.010","volume":"128","author":"T Yin","year":"2011","unstructured":"Yin T, Miyata T (2011) Pharmacogenomics of clopidogrel: evidence and perspectives. Thromb Res 128:307\u2013316","journal-title":"Thromb Res"},{"key":"3613_CR4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.thromres.2005.03.001","volume":"116","author":"DJ Angiolillo","year":"2005","unstructured":"Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ram\u00edrez C, Cavallari U, Trabetti E et al (2005) Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res 116:491\u2013497","journal-title":"Thromb Res"},{"key":"3613_CR5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/bmc.1128","volume":"23","author":"R Mullangi","year":"2009","unstructured":"Mullangi R, Srinivas NR (2009) Clopidogrel: review of bioanalytical methods, pharmacokinetics\/pharmacodynamics, and update on recent trends in drug\u2013drug interaction studies. Biomed Chromatogr 23:26\u201341","journal-title":"Biomed Chromatogr"},{"key":"3613_CR6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.0306-5251.2001.01453.x","volume":"52","author":"AA Weber","year":"2001","unstructured":"Weber AA, Braun M, Hohlfeld T, Schwippert B, Tsch\u00f6pe D, Schr\u00f6r K (2001) Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. Br J Clin Pharmacol 52:333\u2013336","journal-title":"Br J Clin Pharmacol"},{"key":"3613_CR7","doi-asserted-by":"crossref","unstructured":"Giusti B (2010) Determinants to optimize response to clopidogrel in acute coronary syndrome. Pharmacogenomics Pers Med 33-50","DOI":"10.2147\/PGPM.S5056"},{"key":"3613_CR8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4137\/CMC.S4323","volume":"4","author":"C Terpening","year":"2010","unstructured":"Terpening C (2010) Clopidogrel: a pharmacogenomic perspective on its use in coronary artery disease. Clin Med Insights Cardiol 4:117\u2013128","journal-title":"Clin Med Insights Cardiol"},{"key":"3613_CR9","first-page":"68","volume":"61","author":"S Guha","year":"2009","unstructured":"Guha S, Sardar P, Guha P, Roy S, Mookerjee S, Chakrabarti P et al (2009) Dual antiplatelet drug resistance in patients with acute coronary syndrome. Indian Heart J 61:68\u201373","journal-title":"Indian Heart J"},{"key":"3613_CR10","first-page":"543","volume":"60","author":"VS Thomson","year":"2008","unstructured":"Thomson VS, John B, Pati PK, George OK, George PV, Jose J (2008) Nonresponders to clopidogrel therapy among Indian patients undergoing elective\/adhoc angioplasty. Indian Heart J 60:543\u2013547","journal-title":"Indian Heart J"},{"key":"3613_CR11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1160\/TH04-05-0305","volume":"92","author":"K Schr\u00f6r","year":"2004","unstructured":"Schr\u00f6r K, Weber AA, Hohlfeld T (2004) Clopidogrel \u201cresistance\u201d. Thromb Haemost 92:229\u2013231","journal-title":"Thromb Haemost"},{"key":"3613_CR12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.thromres.2006.08.012","volume":"120","author":"PA Gurbel","year":"2007","unstructured":"Gurbel PA, Tantry US (2007) Clopidogrel resistance? Thromb Res 120:311\u2013321","journal-title":"Thromb Res"},{"key":"3613_CR13","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1177\/0091270009332433","volume":"49","author":"NF Ford","year":"2009","unstructured":"Ford NF (2009) Clopidogrel resistance: pharmacokinetic or pharmacogenetic? J Clin Pharmacol 49:506\u2013512","journal-title":"J Clin Pharmacol"},{"key":"3613_CR14","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1503\/cmaj.060502","volume":"174","author":"J Turgeon","year":"2006","unstructured":"Turgeon J, Pharand C, Michaud V (2006) Understanding clopidogrel efficacy in the presence of cytochrome P450 polymorphism. CMAJ 174:1729","journal-title":"CMAJ"},{"key":"3613_CR15","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00228-008-0471-0","volume":"64","author":"K-A Kim","year":"2008","unstructured":"Kim K-A, Park P-W, Park J-Y (2008) Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects. Eur J Clin Pharmacol 64:589\u2013597","journal-title":"Eur J Clin Pharmacol"},{"key":"3613_CR16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.etap.2009.12.001","volume":"29","author":"V Kumar","year":"2010","unstructured":"Kumar V, Singh S, Yadav CS, Ahmed RS, Gupta S, Pasha ST et al (2010) CYP1A1 and CYP3A4 polymorphic variations in Delhi population of Northern India. Environ Toxicol Pharmacol 29:126\u2013130","journal-title":"Environ Toxicol Pharmacol"},{"key":"3613_CR17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1472-8206.2010.00917.x","volume":"26","author":"D Krishnakumar","year":"2012","unstructured":"Krishnakumar D, Gurusamy U, Dhandapani K, Surendiran A, Baghel R, Kukreti R et al (2012) Genetic polymorphisms of drug-metabolizing phase I enzymes CYP2E1, CYP2A6 and CYP3A5 in South Indian population. Fundam Clin Pharmacol 26:295\u2013306","journal-title":"Fundam Clin Pharmacol"},{"key":"3613_CR18","doi-asserted-by":"crossref","unstructured":"Subraja K, Dkhar SA, Priyadharsini R, Ravindra BK, Shewade DG, Satheesh S et al. Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population. Eur J Clin Pharmacol 69:415\u2013422","DOI":"10.1007\/s00228-012-1381-8"},{"key":"3613_CR19","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/bmc.697","volume":"20","author":"E Souri","year":"2006","unstructured":"Souri E, Jalalizadeh H, Kebriaee-Zadeh A, Shekarchi M, Dalvandi A (2006) Validated HPLC method for determination of carboxylic acid metabolite of clopidogrel in human plasma and its application to a pharmacokinetic study. Biomed Chromatogr 20:1309\u20131314","journal-title":"Biomed Chromatogr"},{"key":"3613_CR20","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1373\/clinchem.2005.059535","volume":"52","author":"BT Ivandic","year":"2006","unstructured":"Ivandic BT, Schlick P, Staritz P, Kurz K, Katus HA, Giannitsis E (2006) Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor. Clin Chem 52:383\u2013388","journal-title":"Clin Chem"},{"key":"3613_CR21","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.2146\/ajhp060662","volume":"65","author":"J Sullivan","year":"2008","unstructured":"Sullivan J, Amarshi N (2008) Dual antiplatelet therapy with clopidogrel and aspirin. Am J Health Syst Pharm 65:1134\u20131143","journal-title":"Am J Health Syst Pharm"},{"key":"3613_CR22","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1161\/01.ATV.0000145980.39477.a9","volume":"24","author":"M Cattaneo","year":"2004","unstructured":"Cattaneo M (2004) Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 24:1980\u20131987","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3613_CR23","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/01.CIR.102.6.624","volume":"102","author":"ME Bertrand","year":"2000","unstructured":"Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH (2000) Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102:624\u2013629","journal-title":"Circulation"},{"key":"3613_CR24","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/eurheartj\/ehi684","volume":"27","author":"TH Wang","year":"2006","unstructured":"Wang TH, Bhatt DL, Topol EJ (2006) Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 27:647\u2013654","journal-title":"Eur Heart J"},{"key":"3613_CR25","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3109\/09537104.2011.579648","volume":"22","author":"G Campo","year":"2011","unstructured":"Campo G, Miccoli M, Tebaldi M, Marchesini J, Fileti L, Monti M et al (2011) Genetic determinants of on-clopidogrel high platelet reactivity. Platelets 22:399\u2013407","journal-title":"Platelets"},{"key":"3613_CR26","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1538-7836.2008.03004.x","volume":"6","author":"D Sibbing","year":"2008","unstructured":"Sibbing D, Taubert D, Sch\u00f6mig A, Kastrati A, Von Beckerath N (2008) Pharmacokinetics of clopidogrel in patients with stent thrombosis. J Thromb Haemost 6:1230\u20131232","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"3613_CR27","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1160\/THS11-01-0025","volume":"105","author":"I Tentzeris","year":"2011","unstructured":"Tentzeris I, Siller-Matula J, Farhan S, Jarai R, Wojta J, Huber K (2011) Platelet function variability and non-genetic causes. Thromb Haemost 105(Suppl 1):S60\u2013S66","journal-title":"Thromb Haemost"},{"key":"3613_CR28","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.jacc.2004.10.079","volume":"45","author":"N Ajzenberg","year":"2005","unstructured":"Ajzenberg N, Aubry P, Huisse M-G, Cachier A, El Amara W, Feldman LJ et al (2005) Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study. J Am Coll Cardiol 45:1753\u20131756","journal-title":"J Am Coll Cardiol"},{"key":"3613_CR29","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1055\/s-0037-1613462","volume":"89","author":"I M\u00fcller","year":"2003","unstructured":"M\u00fcller I, Besta F, Schulz C, Massberg S, Sch\u00f6nig A, Gawaz M (2003) Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 89:783\u2013787","journal-title":"Thromb Haemost"},{"key":"3613_CR30","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.jacc.2007.01.094","volume":"49","author":"P Buonamici","year":"2007","unstructured":"Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R et al (2007) Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 49:2312\u20132317","journal-title":"J Am Coll Cardiol"},{"key":"3613_CR31","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.jacc.2007.05.049","volume":"50","author":"DJ Angiolillo","year":"2007","unstructured":"Angiolillo DJ, Bernardo E, Sabat\u00e9 M, Jimenez-Quevedo P, Costa MA, Palazuelos J et al (2007) Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 50:1541\u20131547","journal-title":"J Am Coll Cardiol"},{"key":"3613_CR32","first-page":"169","volume":"16","author":"DJ Angiolillo","year":"2004","unstructured":"Angiolillo DJ, Fern\u00e1ndez-Ortiz A, Bernardo E, Barrera Ram\u00edrez C, Sabat\u00e9 M, Fernandez C et al (2004) Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol 16:169\u2013174","journal-title":"J Invasive Cardiol"},{"key":"3613_CR33","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1210\/jc.2004-0137","volume":"90","author":"H Matsuno","year":"2005","unstructured":"Matsuno H, Tokuda H, Ishisaki A, Zhou Y, Kitajima Y, Kozawa O (2005) P2Y12 receptors play a significant role in the development of platelet microaggregation in patients with diabetes. J Clin Endocrinol Metab 90:920\u2013927","journal-title":"J Clin Endocrinol Metab"},{"key":"3613_CR34","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.amjcard.2013.09.011","volume":"113","author":"M Pankert","year":"2014","unstructured":"Pankert M, Quilici J, Loundou AD, Verdier V, Lambert M, Deharo P et al (2014) Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting. Am J Cardiol 113:54\u201359","journal-title":"Am J Cardiol"},{"key":"3613_CR35","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.amjcard.2009.07.015","volume":"104","author":"N Bonello-Palot","year":"2009","unstructured":"Bonello-Palot N, Armero S, Paganelli F, Mancini J, De Labriolle A, Bonello C et al (2009) Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. Am J Cardiol 104:1511\u20131515","journal-title":"Am J Cardiol"},{"key":"3613_CR36","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.thromres.2009.06.012","volume":"124","author":"T Gremmel","year":"2009","unstructured":"Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW (2009) Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy. Thromb Res 124:588\u2013591","journal-title":"Thromb Res"},{"key":"3613_CR37","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1161\/01.CIR.0000112378.09325.F9","volume":"109","author":"WC Lau","year":"2004","unstructured":"Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DGM et al (2004) Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 109:166\u2013171","journal-title":"Circulation"},{"key":"3613_CR38","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1161\/01.ATV.0000223867.25324.1a","volume":"26","author":"DJ Angiolillo","year":"2006","unstructured":"Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ram\u00edrez C, Cavallari U, Trabetti E et al (2006) Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 26:1895\u20131900","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3613_CR39","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1503\/cmaj.060664","volume":"174","author":"J-W Suh","year":"2006","unstructured":"Suh J-W, Koo B-K, Zhang S-Y, Park K-W, Cho J-Y, Jang I-J et al (2006) Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 174:1715\u20131722","journal-title":"CMAJ"},{"key":"3613_CR40","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2217\/14622416.9.9.1251","volume":"9","author":"T Geisler","year":"2008","unstructured":"Geisler T, Schaeffeler E, Dippon J, Winter S, Buse V, Bischofs C et al (2008) CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 9:1251\u20131259","journal-title":"Pharmacogenomics"},{"key":"3613_CR41","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","volume":"360","author":"T Simon","year":"2009","unstructured":"Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, M\u00e9neveau N et al (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360:363\u2013375","journal-title":"N Engl J Med"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-014-3613-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11033-014-3613-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-014-3613-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T15:27:42Z","timestamp":1565710062000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11033-014-3613-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,12]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["3613"],"URL":"https:\/\/doi.org\/10.1007\/s11033-014-3613-8","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,12]]}}}